Tenax Therapeutics (TENX) Price & Analysis

Q: What was Tenax Therapeutics’s price range in the past 12 months?

Tenax Therapeutics lowest stock price was $4.63 and its highest was $9.70 in the past 12 months.

Q: What is Tenax Therapeutics’s market cap?

Tenax Therapeutics’s market cap is $56.19M.

Q: When is Tenax Therapeutics’s upcoming earnings report date?

Tenax Therapeutics’s upcoming earnings report date is Mar 26, 2026 which is in 119 days.

Q: How were Tenax Therapeutics’s earnings last quarter?

Tenax Therapeutics released its earnings results on Nov 12, 2025. The company reported -$0.4 earnings per share for the quarter, missing the consensus estimate of -$0.312 by -$0.088.

Q: Is Tenax Therapeutics overvalued?

According to Wall Street analysts Tenax Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Q: Does Tenax Therapeutics pay dividends?

Tenax Therapeutics does not currently pay dividends.

Q: What is Tenax Therapeutics’s EPS estimate?

Tenax Therapeutics’s EPS estimate is -0.42.

Q: How many shares outstanding does Tenax Therapeutics have?

Tenax Therapeutics has 6,243,575 shares outstanding.

Q: What happened to Tenax Therapeutics’s price movement after its last earnings report?

Tenax Therapeutics reported an EPS of -$0.4 in its last earnings report, missing expectations of -$0.312. Following the earnings report the stock price went down -4.292%.

Q: Which hedge fund is a major shareholder of Tenax Therapeutics?

Currently, no hedge funds are holding shares in TENX

Compare

592 Followers

TENX Stock Chart & Stats

$9.40

<$0.01(0.16%)

At close: Jan 08 4:00 PM EST

$9.40

<$0.01(0.16%)

Day’s Range― - ―

52-Week Range$4.63 - $9.70

Previous CloseN/A

Volume25.45K

Average Volume (3M)77.07K

Market Cap

$56.19M

Enterprise Value$203.06M

Total Cash (Recent Filing)$99.37M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta0.66

Next Earnings

Mar 26, 2026

EPS Estimate

-0.42

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.40

Shares Outstanding6,243,575

10 Day Avg. Volume87,220

30 Day Avg. Volume77,066

Financial Highlights & Ratios

PEG Ratio0.06

Price to Book (P/B)1.03

Price to Sales (P/S)0.00

P/FCF Ratio-6.38

Enterprise Value/Market Cap3.61

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-4.69

Forecast

1Y Price Target

$25.00

Price Target Upside165.96% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

EPS Forecast (FY)-1.36

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical DevelopmentTenax remains on track to initiate a second registrational Phase III (LEVEL-2) study of oral levosimendan this year.

Patent ProtectionThe European Patent Office plans to grant patent protection in Europe for the use of levosimendan in pulmonary hypertension resulting from heart failure with preserved ejection fraction.

Patient OutcomesAnecdotal patient improvements in the LEVEL OLE portion are an encouraging signal.

Bears Say

Financial PerformanceR&D and SG&A expenses for the quarter were higher than expected, totaling $6 million each.

Regulatory RisksClinical, regulatory, commercial and financing risks exist for TNX-103 in Group 2 PH-HFpEF.

Timeline DelaysThe timeline for the Ph3 LEVEL Study in PH-HFpEF has been delayed, with topline data now expected in the second half of 2026.

Tenax Therapeutics News

Tenax Therapeutics to hold a conference call

Conference call to discuss TNX-103 (Oral Levosimendan) for the Treatment of PH-HFpEF will be held on November 13...

14d ago

TENX

Tenax Therapeutics reports Q3 EPS (40c), consensus ($1.12)

“We continued to advance our lead program, TNX-103, in patients with PH-HFpEF and remain on track to enroll...

15d ago

TENX

Tenax Therapeutics Reports Increased R&D Expenses Amid Clinical Trials

Tenax Therapeutics ( ($TENX) ) has released its Q3 earnings. Here is a breakdown of the information Tenax...

15d ago

TENX

TENX Earnings this Week: How Will it Perform?

Tenax Therapeutics (TENX) is scheduled to report 3rd quarter earnings on 11/12/2025. Regarding Q3 estimates, Wall Street analysts...

17d ago

TENX

Tenax Therapeutics Advances Phase 3 Study on Levosimendan for PH-HFpEF

Tenax Therapeutics (($TENX)), Medpace Holdings Inc (($MEDP)) announced an update on their ongoing clinical study. Tenax Therapeutics, in...

1M ago

MEDP

TENX

Tenax Therapeutics management to meet with Piper Sandler

Meeting to be held in New York on October 8-9 hosted by Piper Sandler. Published first on TheFly...

2M ago

TENX

Optimistic Buy Rating for Tenax Therapeutics Driven by Strong Patent Portfolio and Market Potential of Levosimendan

William Blair analyst Matt Phipps has reiterated their bullish stance on TENX stock, giving a Buy rating on...

2M ago

TENX

Tenax announces EPO intention to grant patent for levosimendan in PH-HFpEF

Tenax Therapeutics (TENX) announced that the European Patent Office, EPO, has notified Tenax of its Intention to Grant...

2M ago

TENX

Tenax Therapeutics Expands Licensing Agreement with Orion

Tenax Therapeutics ( ($TENX) ) just unveiled an update. On September 3, 2025, Tenax Therapeutics expanded its licensing...

3M ago

TENX

Promising Potential of Tenax Therapeutics’ TNX-103 Drives Buy Rating Amid Positive Phase 2 Results and Anticipated Phase 3 Trial

Yasmeen Rahimi, an analyst from Piper Sandler, has initiated a new Buy rating on Tenax Therapeutics (TENX). Yasmeen...

3M ago

TENX

Tenax Therapeutics initiated with an Overweight at Piper Sandler

Piper Sandler analyst Yasmeen Rahimi initiated coverage of Tenax Therapeutics (TENX) with an Overweight rating and $20 price...

3M ago

TENX

Tenax Therapeutics Reports Q2 2025 Financial Results

Tenax Therapeutics ( ($TENX) ) has released its Q2 earnings. Here is a breakdown of the information Tenax...

4M ago

TENX

Tenax Therapeutics reports Q2 EPS (27c), consensus (45c)

“We are pleased with the progress achieved in the second quarter, and remain in a strong position to...

4M ago

TENX

Tenax Therapeutics trading resumes

13:44 EDT Tenax Therapeutics (TENX) trading resumes Published first on TheFly – the ultimate source for real-time, market-moving...

5M ago

TENX

TENX FAQ

What was Tenax Therapeutics’s price range in the past 12 months?

Tenax Therapeutics lowest stock price was $4.63 and its highest was $9.70 in the past 12 months.

What is Tenax Therapeutics’s market cap?

Tenax Therapeutics’s market cap is $56.19M.

When is Tenax Therapeutics’s upcoming earnings report date?

Tenax Therapeutics’s upcoming earnings report date is Mar 26, 2026 which is in 119 days.

How were Tenax Therapeutics’s earnings last quarter?

Tenax Therapeutics released its earnings results on Nov 12, 2025. The company reported -$0.4 earnings per share for the quarter, missing the consensus estimate of -$0.312 by -$0.088.

Is Tenax Therapeutics overvalued?

According to Wall Street analysts Tenax Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Tenax Therapeutics pay dividends?

Tenax Therapeutics does not currently pay dividends.

What is Tenax Therapeutics’s EPS estimate?

Tenax Therapeutics’s EPS estimate is -0.42.

How many shares outstanding does Tenax Therapeutics have?

Tenax Therapeutics has 6,243,575 shares outstanding.

What happened to Tenax Therapeutics’s price movement after its last earnings report?

Tenax Therapeutics reported an EPS of -$0.4 in its last earnings report, missing expectations of -$0.312. Following the earnings report the stock price went down -4.292%.

Which hedge fund is a major shareholder of Tenax Therapeutics?

Currently, no hedge funds are holding shares in TENX

Tenax Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-44.80%

Trailing 12-Months

Asset Growth

3.03%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Tenax Therapeutics

Tenax Therapeutics, Inc. is a specialty pharmaceutical company focused on identifying, developing, and commercializing pharmaceutical products for the critical care market. The company primarily operates in the biotechnology and pharmaceutical sectors, with its core product offerings centered around novel therapeutic solutions for pulmonary hypertension and other cardiovascular diseases. Tenax Therapeutics is committed to advancing clinical programs and leveraging its expertise to bring innovative treatments to market that address unmet medical needs.

Tenax Therapeutics (TENX) Earnings & Revenues

Historic Earnings Reports

TENX Stock 12 Month Forecast

Average Price Target

$25.00

▲(165.96% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","31":"$31","9.25":"$9.25","16.5":"$16.5","23.75":"$23.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$30.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$25.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$20.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,9.25,16.5,23.75,31],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.34,9.083076923076923,10.826153846153847,12.569230769230769,14.312307692307693,16.055384615384618,17.798461538461538,19.54153846153846,21.284615384615385,23.02769230769231,24.770769230769233,26.513846153846156,28.256923076923076,{"y":30,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.34,8.698461538461538,10.056923076923077,11.415384615384614,12.773846153846154,14.132307692307691,15.49076923076923,16.84923076923077,18.207692307692305,19.566153846153846,20.924615384615386,22.283076923076923,23.64153846153846,{"y":25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.34,8.313846153846153,9.287692307692307,10.26153846153846,11.235384615384614,12.209230769230768,13.183076923076923,14.156923076923077,15.13076923076923,16.104615384615386,17.07846153846154,18.052307692307693,19.026153846153846,{"y":20,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.99,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.4,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.48,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.19,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.97,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.36,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.73,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.08,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.75,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.22,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.98,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.34,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >